Switching from Invega Sustenna 234 mg to Abilify Maintena LAI
Use gradual cross-titration informed by the half-life and receptor profiles of paliperidone and aripiprazole, starting Abilify Maintena while allowing Invega Sustenna to wash out over several months given its prolonged-release characteristics. 1
Recommended Switching Protocol
Key Pharmacological Considerations
The transition from paliperidone palmitate (Invega Sustenna) to aripiprazole LAI (Abilify Maintena) requires careful planning because:
- Paliperidone is a D2 antagonist while aripiprazole is a D2 partial agonist — these represent fundamentally different pharmacodynamic profiles 1
- Invega Sustenna has an extremely long half-life with sustained release over months, meaning the drug continues to be released long after the last injection 2
- The 234 mg dose represents a high maintenance dose, requiring extended washout consideration
Step-by-Step Switching Algorithm
1. Timing the Switch
- Give the last dose of Invega Sustenna 234 mg as scheduled
- Wait 2-4 weeks before initiating Abilify Maintena to allow partial washout while maintaining antipsychotic coverage
- The prolonged-release characteristics mean paliperidone will continue providing therapeutic coverage during this transition period 1
2. Initiating Abilify Maintena
- Start with oral aripiprazole 10-15 mg daily for 14 consecutive days before the first Abilify Maintena injection to establish tolerability
- Then administer Abilify Maintena 400 mg IM (deltoid or gluteal)
- Continue oral aripiprazole supplementation for 14 days after the first LAI injection
3. Cross-Titration Period
- During weeks 2-8 after starting Abilify Maintena, both medications will be present in the system
- Monitor closely for akathisia/restlessness (occurs in ~10% of patients switching to aripiprazole) 3
- Watch for withdrawal symptoms or symptom breakthrough as paliperidone levels decline
4. Subsequent Dosing
- Give second Abilify Maintena injection at 4 weeks (400 mg)
- Continue monthly thereafter
Critical Monitoring Parameters
Weeks 1-4 (Early Phase)
- Akathisia and motor symptoms: Most akathisia emerges within the first 4 weeks 3
- Psychotic symptom stability: Assess for breakthrough symptoms as paliperidone washes out
- Injection site reactions: Peak in first 2 injections 3
Weeks 4-12 (Transition Phase)
- Prolactin normalization: Expect dramatic decreases (median -4.60 ng/mL in males, -3.55 ng/mL in females with aripiprazole) 3. In one study, 98% of patients had elevated prolactin on paliperidone, dropping to only 6.3% after 6 months on aripiprazole 4
- Sexual function improvement: 81.3% reported sexual dysfunction on paliperidone vs 56.3% after 6 months on aripiprazole 4
- Weight monitoring: Both agents can cause weight gain; aripiprazole shows no clear metabolic advantage over paliperidone 5
Months 3-6 (Stabilization Phase)
- Continue monitoring for late-emerging symptoms
- Assess overall symptom control and quality of life
Common Pitfalls to Avoid
Do NOT abruptly stop Invega Sustenna — the depot will continue releasing for months regardless, and abrupt cessation of coverage could lead to relapse 1
Do NOT skip oral aripiprazole supplementation during Abilify Maintena initiation — this is critical for establishing therapeutic levels quickly
Do NOT ignore early akathisia — it typically emerges within 4 weeks and may require dose adjustment or adjunctive treatment 3
Do NOT expect immediate metabolic benefits — while prolactin normalizes rapidly, weight gain can occur with both agents 5
Special Considerations
If Patient Develops Severe Side Effects
- The long half-life of paliperidone means side effects from the 234 mg dose may persist for weeks to months 6
- Consider using therapeutic drug monitoring via prolactin levels if direct drug level measurement is unavailable 6
- Severe Parkinsonism has been reported with paliperidone loading doses and may require extended management 6
Rationale for This Approach
The 2025 INTEGRATE guidelines emphasize that "antipsychotic switching should involve gradual cross-titration informed by the half-life and receptor profile of each medication" 1. Given that you're switching from a D2 antagonist (paliperidone) to a D2 partial agonist (aripiprazole), this represents a significant pharmacodynamic shift requiring careful overlap to prevent symptom breakthrough while minimizing side effects.
The evidence shows this switch can improve prolactin-related side effects and sexual function 4, but does not reliably reduce weight gain 5, so set appropriate patient expectations regarding metabolic outcomes.